Lyell Immunopharma LYEL 深 沪
等待开盘 10-07 09:30:00 美东时间
17.85
+0.100
+0.56%
华盛通- 最 高18.3047
- 今 开17.97
- 成交量 3.62万股
- 最 低 17.40
- 昨 收 17.75
- 总市值 3.43亿
- 52周最高 29.998
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 7.65
- 委 比 -98.02%
- 总股本 1921.12万
- 历史最高 396.80
- 量 比 0.65
- 振 幅 5.10%
- 历史最低 7.80
- 每 手 1
- 风险率 0.46%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅485.44%！Allarity Therapeutics获机构升目标价至9.25美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Allarity Therapeutics"买入"评级，目标价从9美元升至9.25美元；JMP证券：维持Crinetics Pharmaceuticals"跑赢大市"评级，目标价从86美元升至143美元
09-29 09:15
LUCID CAPITAL MARKETS Initiates Coverage On Lyell Immunopharma with Buy Rating, Announces Price Target of $20
LUCID CAPITAL MARKETS analyst Christopher Liu initiates coverage on Lyell Immunopharma (NASDAQ: LYEL) with a Buy rating and announces Price Target of $20.
09-26 19:22
Lyell Immunopharma CFO Resignation Announced
Lyell Immunopharma ( ($LYEL) ) has issued an update. On September 15, 2025, Cha...
09-17 04:53
Lyell Immunopharma CFO Charles Newton To Resign Effective October 31, 2025
On September 15, 2025, Charles Newton notified Lyell Immunopharma, Inc. (the "Company") of his decision to resign from his position as the Chief Financial Officer and principal financial and accounting officer of
09-17 04:24
Lyell Immunopharma Initiates Pinacle - H2H, Phase 3 Head-To-Head CAR T-Cell Therapy Randomized Controlled Trial; Forms Steering Committee Of Preeminent Lymphoma Experts
PiNACLE - H2H will evaluate rondecabtagene autoleucel (ronde-cel) versus investigator's choice of approved CD19 CAR T-cell therapies in patients with aggressive large B-cell lymphoma receiving treatment in the second
09-03 20:10
Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee
Lyell Immunopharma has initiated the PiNACLE - H2H Phase 3 trial, a head-to-head comparison of its dual-targeting CD19/CD20 CAR T-cell therapy, ronde-cel, against approved CD19 CAR T-cell therapies for relapsed or refractory large B-cell lymphoma (LBCL) in the second-line setting. Ronde-cel targets both CD19 and CD20 to potentially improve response rates and durability. A Steering Committee of lymphoma experts has been formed to guide the trial, ...
09-03 12:00
Lyell Immunopharma Announces Participation in September Investor Conferences
Lyell Immunopharma announced that its senior management will participate in two investor conferences: the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8th and the H.C. Wainwright 27th Annual Global Investment Conference on September 10th. The company's lead product, LYL314, a next-generation CAR T-cell therapy, is being evaluated in the PiNACLE trial for large B-cell lymphoma. Lyell's manufacturing center, LyFE, has commer...
09-02 20:05
Lyell Immunopharma reports Q2 results
Lyell Immunopharma press release (NASDAQ:LYEL): Q2 net loss of $42.7 million Revenue of $8K, vs. $13K a year ago More on Lyell Immunopharma Lyell: 'Hold' Rating Based On Phase 3 LYL314 LBCL Treatment ...
08-13 05:06
Lyell Immunopharma Q2 EPS $(2.89) Beats $(3.82) Estimate, Sales $8.000K Down From $13.000K YoY
Lyell Immunopharma (NASDAQ:LYEL) reported quarterly losses of $(2.89) per share which beat the analyst consensus estimate of $(3.82) by 24.4 percent. This is a 19.5 percent increase over losses of $(3.59) per share from
08-13 04:34
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers 4D Molecular Therapeutics (NASDAQ:FDMT) shares moved upwards by 33.1% ...
08-01 05:07
